Literature DB >> 16216863

Anaemia is associated with higher mortality among patients with heart failure with preserved systolic function.

L Grigorian Shamagian1, A Varela Roman, J M Garcia-Acuña, P Mazon Ramos, A Virgos Lamela, J R Gonzalez-Juanatey.   

Abstract

OBJECTIVE: To investigate the prevalence of anaemia and its influence on mortality among hospitalised patients with congestive heart failure (CHF) with preserved left ventricular systolic function (LVSF). METHOD AND
RESULTS: 210 patients with preserved LVSF admitted to the cardiology department of a tertiary hospital for CHF between 1 January 2000 and 31 December 2002 were analysed. Anaemic patients, who constituted 46% of the whole group, were older (75 v 72 years, p = 0.036); were in hospital longer (mean (SD) 13 v 11 days, p = 0.007); had a higher prevalence of ischaemic heart disease (54% v 35%, p = 0.009), left bundle branch block (12% v 4%, p = 0.018), and kidney failure (56% v 34%, p = 0.003); and had faster erythrocyte sedimentation rates (mean (SD) 50 v 26 mm in the first hour, p < 0.001), a tendency to lower serum cholesterol concentration (mean (SD) 4.65 v 5.22 mmol/l, p = 0.073), and smaller body mass index (mean (SD) 27 v 29 kg/m2, p = 0.126) than their non-anaemic counterparts. Kaplan-Meier analysis showed the anaemic group to have significantly poorer survival (p = 0.0001), with a one year survival rate of 72.2% versus 90.5% in the non-anaemic group. Multivariate analysis showed anaemia to be the most powerful independent predictor of mortality, increasing the risk of death by a factor of 2.7 (p = 0.007).
CONCLUSION: Anaemia is a very prevalent condition in hospitalised patients with CHF with preserved LVSF and is independently associated with higher mortality. Appropriately designed randomised studies are needed to determine whether the prevention or treatment of anaemia can improve survival of these patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16216863      PMCID: PMC1860665          DOI: 10.1136/hrt.2005.064394

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  28 in total

1.  Guidelines for the diagnosis and treatment of chronic heart failure.

Authors:  W J Remme; K Swedberg
Journal:  Eur Heart J       Date:  2001-09       Impact factor: 29.983

2.  The prevalence of anemia in chronic heart failure.

Authors:  Hildegard Tanner; Giorgio Moschovitis; Gabriela M Kuster; Roger Hullin; Dorothy Pfiiffner; Otto M Hess; Paul Mohacsi
Journal:  Int J Cardiol       Date:  2002-11       Impact factor: 4.164

3.  Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure.

Authors:  Tamara B Horwich; Gregg C Fonarow; Michele A Hamilton; W Robb MacLellan; Jeff Borenstein
Journal:  J Am Coll Cardiol       Date:  2002-06-05       Impact factor: 24.094

4.  Heart failure in patients with preserved and deteriorated left ventricular ejection fraction.

Authors:  A Varela-Roman; L Grigorian; E Barge; P Bassante; M G de la Peña; J R Gonzalez-Juanatey
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

5.  The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction.

Authors:  D L Dries; D V Exner; M J Domanski; B Greenberg; L W Stevenson
Journal:  J Am Coll Cardiol       Date:  2000-03-01       Impact factor: 24.094

6.  The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations.

Authors:  D S Silverberg; D Wexler; M Blum; G Keren; D Sheps; E Leibovitch; D Brosh; S Laniado; D Schwartz; T Yachnin; I Shapira; D Gavish; R Baruch; B Koifman; C Kaplan; S Steinbruch; A Iaina
Journal:  J Am Coll Cardiol       Date:  2000-06       Impact factor: 24.094

7.  Renal function, neurohormonal activation, and survival in patients with chronic heart failure.

Authors:  H L Hillege; A R Girbes; P J de Kam; F Boomsma; D de Zeeuw; A Charlesworth; J R Hampton; D J van Veldhuisen
Journal:  Circulation       Date:  2000-07-11       Impact factor: 29.690

8.  The prognostic importance of anemia in patients with heart failure.

Authors:  Mikhail Kosiborod; Grace L Smith; Martha J Radford; JoAnne M Foody; Harlan M Krumholz
Journal:  Am J Med       Date:  2003-02-01       Impact factor: 4.965

9.  Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure.

Authors:  Justin A Ezekowitz; Finlay A McAlister; Paul W Armstrong
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

10.  Hemodilution is common in patients with advanced heart failure.

Authors:  Ana-Silvia Androne; Stuart D Katz; Lars Lund; John LaManca; Alhakam Hudaihed; Katarzyna Hryniewicz; Donna M Mancini
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

View more
  4 in total

1.  The effect of erythropoietin on exercise capacity, left ventricular remodeling, pressure-volume relationships, and quality of life in older patients with anemia and heart failure with preserved ejection fraction.

Authors:  Rose S Cohen; Paula Karlin; Madeline Yushak; Donna Mancini; Mathew S Maurer
Journal:  Congest Heart Fail       Date:  2010 May-Jun

Review 2.  Anemia and the potential role of erythropoiesis-stimulating agents in heart failure.

Authors:  Haroon A Faraz; Syed F Zafar; Jalal K Ghali
Journal:  Curr Heart Fail Rep       Date:  2008-06

Review 3.  The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes.

Authors:  Yi-Da Tang; Stuart D Katz
Journal:  Heart Fail Rev       Date:  2008-02-02       Impact factor: 4.214

4.  [Heart failure with preserved ejection fraction in sub-Saharan Africa: about 32 cases].

Authors:  Mouhamed Cherif Mboup; Khadidiatou Dia; Pape Diadie Fall
Journal:  Pan Afr Med J       Date:  2013-11-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.